Int J Gynecol Cancer. 2018 Jun;28(5):945-950. doi: 10.1097/IGC.0000000000001247.
This study aimed to survey all practicing certified gynecological oncologists (CGOs) in Australia and New Zealand to determine their current surgical practice for primary advanced epithelial ovarian cancer (EOC) and compare the findings with an identical survey conducted 10 years previously.
METHODS/MATERIALS: A questionnaire was e-mailed to all 53 practicing CGOs in Australia and New Zealand in July 2017 assessing their definition of optimal debulking for EOC, their use of neoadjuvant chemotherapy, and the surgical procedures they use to achieve cytoreduction. Results were compared with an identical study performed in 2007 using χ and logistic regression analysis.
Response rate was 89% (47/53). A higher percentage of patients received neoadjuvant chemotherapy before surgery in 2017 than in 2007 (43% vs 16%, respectively). In 2017, CGOs were more likely to define optimal debulking as zero residual disease (R0; 21/44 [48%] vs 6/34 [18%], P < 0.001). To achieve this, CGOs were significantly more likely to independently perform stripping/resection of the diaphragm (44/47 [94%] vs 15/34 [44%], P < 0.001) and, with assistance from surgical colleagues, perform resection of upper para-aortic lymph nodes (39/46 [85%] vs 21/34 [62%], P = 0.02) and parenchymal liver metastases (30/46 [65%] vs 13/34 [38%], P = 0.02). They were now less likely to resect/reimplant the ureter without assistance (23% vs 53%, P = 0.01). A surgeon's definition of optimal debulking as R0 was significantly associated with a high use of neoadjuvant chemotherapy (in ≥50% of patients).
Certified gynecological oncologists' definition of optimal debulking for primary EOC is more likely to be R0 in 2017 than in 2007. Radical abdominal surgery was performed more often in 2017, requiring assistance by a surgical colleague in many cases. An increased use of neoadjuvant chemotherapy was the only factor significantly associated with CGOs' definition of optimal debulking as R0.
本研究旨在调查澳大利亚和新西兰所有执业的认证妇科肿瘤医生(CGO),以确定他们目前对原发性高级上皮性卵巢癌(EOC)的手术治疗方法,并将调查结果与 10 年前进行的相同调查进行比较。
方法/材料:2017 年 7 月,我们向澳大利亚和新西兰的 53 名执业 CGO 发送了一份电子问卷,评估他们对 EOC 最佳减瘤定义、新辅助化疗使用情况以及他们用于实现细胞减灭术的手术程序。结果与 2007 年进行的一项相同研究进行了比较,采用 χ2 和逻辑回归分析。
回复率为 89%(47/53)。与 2007 年相比,2017 年接受新辅助化疗的患者比例更高(分别为 43%和 16%)。在 2017 年,CGO 更有可能将无残留疾病(R0)定义为最佳减瘤(44/47 [94%] vs 6/34 [18%],P <0.001)。为了实现这一目标,CGO 更有可能独立进行膈膜剥离/切除(44/47 [94%] vs 15/34 [44%],P <0.001),并在外科同事的协助下,进行上腔淋巴结切除术(39/46 [85%] vs 21/34 [62%],P = 0.02)和实质性肝转移切除术(30/46 [65%] vs 13/34 [38%],P = 0.02)。他们现在不太可能在没有帮助的情况下切除/再植入输尿管(23%比 53%,P = 0.01)。外科医生对最佳减瘤的定义为 R0 与新辅助化疗的高使用率(≥50%的患者)显著相关。
2017 年,CGO 对原发性 EOC 的最佳减瘤定义更有可能为 R0,而不是 2007 年。2017 年进行了更多的根治性腹部手术,在许多情况下需要外科同事的协助。新辅助化疗的使用增加是唯一与 CGO 定义 R0 作为最佳减瘤相关的显著因素。